NEW ORLEANS, LOUISIANA – At the 86th Scientific Sessions of the American Diabetes Association (ADA) held in New Orleans, Louisiana,…
Read More

NEW ORLEANS, LOUISIANA – At the 86th Scientific Sessions of the American Diabetes Association (ADA) held in New Orleans, Louisiana,…
Read More
The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer. The 2026…
Read More
The detection of electromagnetic radiation across various spectra serves as the backbone of modern technological infrastructure, facilitating everything from fiber-optic…
Read More
The landscape of global cybersecurity is on the precipice of a paradigm shift as researchers move closer to realizing a…
Read More
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
A collaborative research effort led by the Institute of Ion Beam Physics and Materials Research at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR)…
Read More
Eli Lilly’s investigational drug, retatrutide, a pioneering first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, has delivered extraordinary results…
Read More
A collaborative research effort led by the Institute of Ion Beam Physics and Materials Research at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR)…
Read More